PDF(Pubmed)
Abstract：
BACKGROUND: CFAP65 (cilia and flagella associated protein 65) is a fundamental protein in the development and formation of ciliated flagella, but few studies have focused on its role in cancer. This study aimed to investigate the prognostic significance of CFAP65 in colon cancer.
METHODS: The functionally enriched genes related to CFAP65 were analyzed through the Gene Ontology (GO) database. Subsequently, CFAP65 expression levels in colon cancer were evaluated by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) and immunoblotting in 20 pairs of frozen samples, including tumors and their matched paratumor tissue. Furthermore, protein expression of CFAP65 in 189 colon cancer patients were assessed via immunohistochemical staining. The correlations between CFAP65 expression and clinical features as well as long-term survival were statistically analyzed.
RESULTS: CFAP65-related genes are significantly enriched on cellular processes of cell motility, ion channels, and GTPase-associated signaling. The expression of CFAP65 was significantly higher in colon cancer tissue compared to paratumor tissue. The proportion of high expression and low expression of CFAP65 in the clinical samples of colon cancer were 61.9% and 38.1%, respectively, and its expression level was not associated with the clinical parameters including gender, age, tumor location, histological differentiation, tumor stage, vascular invasion and mismatch repair deficiency. The five-year disease-free survival rate of the patients with CFAP65 low expression tumors was significantly lower than that those with high expression tumors (56.9% vs. 72.6%, P = 0.03), but the overall survival rate has no significant difference (69% vs. 78.6%, P = 0.171). The cox hazard regression analysis model showed that CFAP65 expression, tumor stage and tumor location were independent prognostic factors.
CONCLUSIONS: In conclusion, we demonstrate CFAP65 is a potential predictive marker for tumor progression in colon cancer.
METHODS: The functionally enriched genes related to CFAP65 were analyzed through the Gene Ontology (GO) database. Subsequently, CFAP65 expression levels in colon cancer were evaluated by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) and immunoblotting in 20 pairs of frozen samples, including tumors and their matched paratumor tissue. Furthermore, protein expression of CFAP65 in 189 colon cancer patients were assessed via immunohistochemical staining. The correlations between CFAP65 expression and clinical features as well as long-term survival were statistically analyzed.
RESULTS: CFAP65-related genes are significantly enriched on cellular processes of cell motility, ion channels, and GTPase-associated signaling. The expression of CFAP65 was significantly higher in colon cancer tissue compared to paratumor tissue. The proportion of high expression and low expression of CFAP65 in the clinical samples of colon cancer were 61.9% and 38.1%, respectively, and its expression level was not associated with the clinical parameters including gender, age, tumor location, histological differentiation, tumor stage, vascular invasion and mismatch repair deficiency. The five-year disease-free survival rate of the patients with CFAP65 low expression tumors was significantly lower than that those with high expression tumors (56.9% vs. 72.6%, P = 0.03), but the overall survival rate has no significant difference (69% vs. 78.6%, P = 0.171). The cox hazard regression analysis model showed that CFAP65 expression, tumor stage and tumor location were independent prognostic factors.
CONCLUSIONS: In conclusion, we demonstrate CFAP65 is a potential predictive marker for tumor progression in colon cancer.
摘要：
背景：CFAP65（纤毛和鞭毛相关蛋白65）是纤毛鞭毛发育和形成中的基本蛋白，但是很少有研究关注它在癌症中的作用。本研究旨在探讨CFAP65在结肠癌中的预后意义。
方法：通过基因本体论（GO）数据库分析了与CFAP65相关的功能富集基因。随后，通过逆转录和定量聚合酶链反应（RT-qPCR）和免疫印迹在20对冷冻样品中评估了结肠癌中CFAP65的表达水平，包括肿瘤及其匹配的副瘤组织。此外，通过免疫组织化学染色评估189例结肠癌患者的CFAP65蛋白表达。统计学分析CFAP65表达与临床特征及长期生存的相关性。
结果：CFAP65相关基因在细胞运动的细胞过程中显著富集，离子通道,和GTPase相关信号。CFAP65在结肠癌组织中的表达明显高于癌旁组织。CFAP65在结肠癌临床标本中高表达和低表达的比例分离为61.9%和38.1%,分别,其表达水平与包括性别在内的临床参数无关，年龄,肿瘤位置,组织学分化，肿瘤分期,血管侵犯和错配修复缺陷。CFAP65低表达肿瘤患者的5年无病生存率明显低于高表达肿瘤患者(56.9%vs.72.6%,P=0.03),但总体生存率无显著差异(69%vs.78.6%,P=0.171）。Cox风险回归分析模型显示,CFAP65表达,肿瘤分期和肿瘤部位是影响预后的独立因素。
结论：结论：我们证明CFAP65是结肠癌肿瘤进展的潜在预测标志物.
方法：通过基因本体论（GO）数据库分析了与CFAP65相关的功能富集基因。随后，通过逆转录和定量聚合酶链反应（RT-qPCR）和免疫印迹在20对冷冻样品中评估了结肠癌中CFAP65的表达水平，包括肿瘤及其匹配的副瘤组织。此外，通过免疫组织化学染色评估189例结肠癌患者的CFAP65蛋白表达。统计学分析CFAP65表达与临床特征及长期生存的相关性。
结果：CFAP65相关基因在细胞运动的细胞过程中显著富集，离子通道,和GTPase相关信号。CFAP65在结肠癌组织中的表达明显高于癌旁组织。CFAP65在结肠癌临床标本中高表达和低表达的比例分离为61.9%和38.1%,分别,其表达水平与包括性别在内的临床参数无关，年龄,肿瘤位置,组织学分化，肿瘤分期,血管侵犯和错配修复缺陷。CFAP65低表达肿瘤患者的5年无病生存率明显低于高表达肿瘤患者(56.9%vs.72.6%,P=0.03),但总体生存率无显著差异(69%vs.78.6%,P=0.171）。Cox风险回归分析模型显示,CFAP65表达,肿瘤分期和肿瘤部位是影响预后的独立因素。
结论：结论：我们证明CFAP65是结肠癌肿瘤进展的潜在预测标志物.
